Ozmosi | Atosiban Drug Profile

Product Description

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Atosiban)

Mechanisms of Action: OXTR Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Ferring
Company Location: Europe
Company Founding Year: 1950
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Obstetric Labor, Premature|Infertility|Pregnancy Outcomes

Phase 3: Obstetric Labor, Premature

Phase 2: Other|Endometriosis|Obstetric Labor, Premature

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT07185230	NCT07185230	N/A	Recruiting	Infertility	2027-06-30	2025-12-11	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT06537778	sPTB	N/A	Completed	Obstetric Labor, Premature	2024-02-12	2024-08-06	Primary Endpoints\|Treatments
NCT06399965	sPTB	N/A	Withdrawn	Obstetric Labor, Premature	2024-02-12	2024-07-05
ChiCTR2200056942	ChiCTR2200056942	N/A	Not yet recruiting	Unknown	2023-12-31
ChiCTR2000030175	ChiCTR2000030175	N/A	Not yet recruiting	Obstetric Labor, Premature	2021-12-30
NCT03904745	Atosiban study	N/A	Unknown status	Infertility, Female\|Infertility, Male	2021-07-30	2022-12-03	Primary Endpoints\|Treatments\|Trial Status
ChiCTR1900022333	ChiCTR1900022333	N/A	Not yet recruiting	Infertility	2020-04-20
NCT04468568	Atosiban Versus Terbutaline	N/A	Completed	Meningomyelocele\|Meningocele\|Pregnancy Outcomes\|Spina Bifida Cystica	2020-01-31	2022-06-07	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
ChiCTR1900020795	ChiCTR1900020795	N/A	Not yet recruiting	Pregnancy Outcomes\|Pregnancy, Ovarian	2019-05-01
NCT03570294	2015/I/17-GW	N/A	Completed	Obstetric Labor, Premature	2018-06-10	2024-06-26	Primary Endpoints\|Treatments
ChiCTR-OOR-16008505	ChiCTR-OOR-16008505	N/A	Not yet recruiting	Infertility	2017-07-01
NCT01493440	IVFAS1103	N/A	Completed	Pregnancy Outcomes	2011-08-01	2019-03-19	Treatments
ChiCTR-IOQ-14005715	ChiCTR-IOQ-14005715	N/A	Completed	Endometriosis	None
NCT02893722	FERRING-001	P1	Unknown status	Vaginal Discharge\|Pregnancy Outcomes\|Infertility\|Dizziness\|Heart Transplant\|Stem Cell Transplant\|Endometriosis\|Flushing\|Heart Failure\|Tremor\|Headache	2018-01-01	2019-03-20	Treatments
NCT00679705	NCT00679705	P1	Completed	Healthy Volunteers	2008-11-01	2025-08-27
NCT05382143	ENDOBAN	P2	Unknown status	Endometriosis	2022-06-01	2024-04-02
NCT01429545	NCT01429545	P2	Completed	Obstetric Labor, Premature	2010-09-01	2019-03-19	Treatments
NCT00587327	OVANCON	P2	Completed	Other	2008-05-01	2019-03-22	Treatments
NCT02725736	755-15-TLV	P3	Unknown status	Obstetric Labor, Premature	2018-03-01	2019-03-20	Treatments
2013-002561-19	Long term tokolysis with atosiban	P3	Terminated	Obstetric Labor, Premature	2015-11-30	2022-03-13	Treatments
NCT01314859	MMC-NIF-2010-01	P3	Withdrawn	Obstetric Labor, Premature	2012-07-01	2019-03-19	Treatments
NCT05693688	APOSTEL 8	P4	Completed	Obstetric Labor, Premature	2024-02-29	2024-07-26	Primary Completion Date\|Primary Endpoints\|Study Completion Date
2017-001007-72	APOSTEL VIII	P4	Active, not recruiting	Obstetric Labor, Premature	2023-06-21	2022-03-13	Treatments
NCT01673399	NCT01673399	P4	Completed	Pregnancy Outcomes	2015-02-01	2025-08-27	Primary Endpoints\|Treatments
NCT01501214	HKUQMHCARE001	P4	Completed	Infertility	2013-12-01	2023-06-28	Primary Endpoints\|Treatments

Recent News Events

Date	Type	Title
04/27/2024	PubMed	The oxytocin antagonist cligosiban reduces human prostate contractility: Implications for the treatment of benign prostatic hyperplasia.
04/22/2024	PubMed	Intracerebroventricular injection of kisspeptin in male rats activates hypothalamo-pituitary-gonadal axis, but not hypothalamo-pituitary-adrenal axis.
04/22/2024	PubMed	Naloxone increases conditioned fear responses during social buffering in male rats.
09/25/2023	News Article	Lamp Carbon Black Market Global Industry Demand, Recent Trends, Share, Size, Revenue and Estimation by 2030 with Top Players
11/22/2022	News Article	XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
07/27/2021	News Article	Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
07/27/2021	News Article	Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Atosiban

Alternative Names: atosiban Clinical Status: Inactive Latest Update: 2025-12-09 Latest Update Note: Clinical Trial Update